
South Korea’s antitrust regulator announced on Thursday, June 3, it has not approved a proposal by major affiliates of Samsung Group to address their alleged unfair business practice over in-house cafeteria business.
Since 2018, the Korea Fair Trade Commission (KFTC) has been investigating Samsung Electronics, Samsung Display, and two other Samsung units over allegations that they have unfairly supported Samsung Welstory, the group’s food service affiliate, by allowing it to run their in-house cafeteria business for them.
In May, Samsung proposed measures to fix its business practice and other supportive steps, including lowering an entry barrier for its cafeteria business to non-affiliated firms.
But the KFTC stated it has decided not to approve Samsung’s proposed corrective measures, stating that they failed to meet some criteria for approval. The regulator will proceed with its review over the level of punitive actions against Samsung.
South Korean law allows a company accused of anti-competitive practices to state a correction scheme without deliberating whether those practices violate the country’s competition act. The move is aimed at speedily resolving such cases and remedying the damage to consumers without resorting to legal means.
Internal trading is blamed here for allowing owner families of conglomerates to easily net large profits by having subsidiaries award lucrative contracts to each other, undermining the principle of fair competition.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas